Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

Abstract Views: 762
PDF: 1062
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Objective: To evaluate the efficacy of the anti-TNFa (Tumor Necrosis Factor alpha) drugs in a variety of pathologic conditions such as psoriatic arthritis, undifferentiated entheso-arthritides, chronic inflammatory bowel diseases, adult onset Still’s disease, Behcet disease. Methods: Review of all published studies evaluating the efficacy of these drugs (mainly infliximab and etanercept, adalimumab to a lesser degree) on the above diseases. Results: Results are reported for each pathologic condition. Both drugs showed to be very efficacious in all the above conditions, except Crohn disease where etanercept does not seem adequate. Conclusions: Both drugs work extremely well, even though comparison between infliximab and etanercept efficacy cannot be performed, due to the lack of a direct comparison.

Altmetrics

Downloads

Download data is not yet available.

Citations

How to Cite



Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases. (2005). Reumatismo, 57(s4), 22-29. https://doi.org/10.4081/reumatismo.2005.4s.22